The brokerage has reduced its pharmacy target valuation from 25x to 22x, resulting in a lower SoTP by Rs 290 per share. “Keeping the hospital multiple intact (24x) and rolling over to FY26, our revised target price is Rs 7,300 (from Rs 7,500); we maintain ‘BUY’,” it said.
| Subscribe To Our Free Newsletter |
